Medicare cancer-drug payment shift may cut access elsewhere

What it does

This bill requires Medicare to pay separately for expensive cancer drugs administered in hospital outpatient settings, rather than bundling their cost into a flat payment for the entire visit. Starting in 2026, cancer drugs costing $350 or more per day are eligible for separate reimbursement based on their actual acquisition cost (average sales price, wholesale cost, or hospital claims data). The bill is budget-neutral—Medicare adjusts other payments to offset the cost of these separate payments.

Why we flagged it

The bill's core mechanism is a reimbursement policy change—carving out separate payment for high-cost cancer drugs from bundled outpatient payments. This is a regulatory/payment reform, not a subsidy or deregulation, though it redistributes Medicare dollars within the system.

What the text implies

• Budget neutrality requirement means Medicare must reduce payments elsewhere in the outpatient system to fund separate cancer-drug payments, potentially affecting access to non-cancer treatments or increasing beneficiary cost-sharing.
• The $350/day threshold and annual adjustment mechanism create a moving target; drugs crossing the threshold in future years will suddenly shift to separate payment, creating unpredictability for hospital billing and potentially incentivizing cost inflation.
• Separate payment based on average sales price or wholesale acquisition cost may incentivize pharmaceutical manufacturers to maintain higher list prices, since separate payment removes the bundling discount that currently applies.
• Hospitals with high volumes of expensive cancer treatments may see improved margins, while those with lower volumes or serving less affluent populations may face disproportionate payment reductions under budget neutrality.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill may improve patient access to newer cancer treatments by ensuring hospitals are reimbursed fairly for expensive drugs, reducing financial barriers to treatment. However, the separate-payment mechanism and budget-neutrality clause mean savings elsewhere in the Medicare system—potentially affecting access to other outpatient services or driving cost-shifting to beneficiaries through higher copays or reduced coverage for non-cancer treatments.

Who stands to gain

• pharmaceutical manufacturers (Johnson & Johnson, Bristol Myers Squibb, others) — higher reimbursemen
• hospitals with high-volume oncology programs — improved reimbursement for expensive cancer drug admi
• specialty pharmacy networks — potential increased volume and margin from separate-payment billing

Named in the bill

Medicare (Centers for Medicare & Medicaid Services), Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY), AIG, Fiserv (FBK), Prudential (PRU), Food and Drug Administration (FDA), Social Security Act Title XVIII

Where it stands

6 cosponsors: 3 Democrats, 3 Republicans.

• Mar 20, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 20, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $70,000 in lobbying spend. A filing names 1 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Neal Dunn, the sponsor, reported $438,583 in PAC receipts in the 2026 cycle.

• Photocure, Inc. — $70,000 on 1 filing

Lobbying Disclosure Act filings through Jul 19, 2026. A filing shows who paid to lobby on a bill it names, not what changed.